Association of Serum Adiponectin, Leptin, and Resistin Concentrations with the Severity of Liver Dysfunction and the Disease Complications in Alcoholic Liver Disease

Table 10

Serum adipokine levels in patients with ALD according to the presence of the disease complications.

	Ascites						𝑃
	Absent (𝑛=58)			Present (𝑛=89)
	Median	95% CI	25–75 P	Median	95% CI	25–75 P
Acrp30 µg/mL	16.94	14.78–23.04	10.16–29.62	23.33	17.93–37.81	14.55–74.20	0.013
Leptin ng/mL	10.47	8.42–11.89	6.34–15.13	6.80	4.40–9.88	2.20–13.32	0.054
Resistin ng/mL	17.15	11.62–24.88	9.33–32.27	16.75	15.13–18.54	11.36–28.08	0.70
	Hepatic encephalopathy						𝑃
	Absent (𝑛=127)			Present (𝑛=20)
	Median	95% CI	25–75 P	Median	95% CI	25–75 P
Acrp30 µg/mL	17.93	16.08–23.38	11.76–41.82	55.65	23.11–164.21	22.62–164.55	0.003
Leptin ng/mL	8.82	6.80–10.49	2.75–14.27	6.42	3.06–12.63	2.76–13.33	0.54
Resistin ng/mL	16.37	14.39–18.91	10.30–29.69	18.17	16.03–20.86	15.83–21.36	0.55
	Oesophageal varices						𝑃
	Absent (𝑛=60)			Present (𝑛=87)
	Median	95% CI	25–75 P	Median	95% CI	25–75 P
Acrp30 µg/mL	17.55	15.20–23.11	11.76–31.42	23.61	17.91–33.14	14.68–51.66	0.16
Leptin ng/mL	8.88	3.66–11.88	2.00–13.94	8.38	5.97–10.13	3.23–13.56	0.69
Resistin ng/mL	18.73	14.40–22.34	9.09–27.24	15.83	13.46–17.53	11.14–28.31	0.59
	Cholestasis						𝑃
	Absent (𝑛=117)			Present (𝑛=30)
	Median	95% CI	25–75 P	Median	95% CI	25–75 P
Acrp30 µg/mL	18.22	16.33–29.60	10.60–68.81	20.10	14.13–25.37	11.76–41.45	0.77
Leptin ng/mL	8.94	7.03–10.69	3.84–15.14	5.23	2.27–10.92	2.00–11.90	0.07
Resistin ng/mL	15.29	13.37–16.99	9.28–26.81	19.74	17.11–31.21	13.46–33.87	0.02
	Renal dysfunction						𝑃
	Creatinine < 1.3 mg/dL (𝑛=125)			Creatinine ≥ 1.3 mg/dL (𝑛=22)
	Median	95% CI	25–75 P	Median	95% CI	25–75 P
Acrp30 µg/mL	18.22	16.65–24.07	11.50–44.27	22.63	17.03–46.19	16.33–161.19	0.12
Leptin ng/mL	9.23	6.80–10.91	3.11–15.00	7.56	2.00–9.08	2.00–10.09	0.18
Resistin ng/mL	16.18	13.46–17.87	10.23–26.08	29.22	16.98–39.77	16.75–63.53	0.001